<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02808429</url>
  </required_header>
  <id_info>
    <org_study_id>MS700461-0035</org_study_id>
    <nct_id>NCT02808429</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Atacicept in IgA Nephropathy</brief_title>
  <official_title>A Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono Research &amp; Development Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, dose response and efficacy of atacicept in
      patients with IgA nephropathy and persistent proteinuria. The study hypothesis is that
      treatment with atacicept will reduce proteinuria compared to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2017</start_date>
  <completion_date type="Anticipated">August 17, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Proportion of subjects with Adverse events (AE), AEs of special interest (AESIs), serious AEs, AEs leading to discontinuation, and AEs leading to death</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Percent change from baseline in proteinuria at Week 48</measure>
    <time_frame>Baseline and Week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: Serum atacicept concentrations</measure>
    <time_frame>Baseline, up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Change from baseline levels in serum immunoglobulin (Ig) classes (IgG, IgA, and IgM)</measure>
    <time_frame>Baseline, up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Change from baseline in serum Galactose Deficient-IgA1 (Gd-IgA1) levels</measure>
    <time_frame>Baseline, up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Change from baseline in serum complement C3 and C4 levels</measure>
    <time_frame>Baseline, up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Change from baseline in immune cell subsets by flow cytometry analysis</measure>
    <time_frame>Baseline, up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Change in urine immuno-electrophoresis pattern</measure>
    <time_frame>Baseline, up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Proportion of subjects positive for Anti-drug antibody assessment</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Proportion of subjects with Clinical significant abnormalities in laboratory assessments, vital signs and electrocardiograms (ECGs)</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Proportion of subjects achieving reduction in proteinuria from Baseline and with stable renal function</measure>
    <time_frame>Baseline, Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change from Baseline in Renal Function</measure>
    <time_frame>Baseline, Week 156</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Serum atacicept concentrations</measure>
    <time_frame>Baseline, up to 180 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change from baseline levels in serum immunoglobulin (Ig) classes (IgG, IgA, and IgM)</measure>
    <time_frame>Baseline, up to 180 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change from baseline in serum Galactose Deficient-IgA1 (Gd-IgA1) levels</measure>
    <time_frame>Baseline, up to 180 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change from baseline in serum complement C3 and C4 levels</measure>
    <time_frame>Baseline, up to 180 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change from baseline in immune cell subsets by flow cytometry analysis</measure>
    <time_frame>Baseline, up to 180 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change in urine immuno-electrophoresis pattern</measure>
    <time_frame>Baseline, up to 180 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Proportion of subjects positive for Anti-drug antibody assessment</measure>
    <time_frame>Up to 180 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Proportion of subjects with AEs, AESIs, AEs leading to discontinuation, SAEs, AEs leading to death</measure>
    <time_frame>Up to 180 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Proportion of subjects with Clinical significant Abnormalities in laboratory assessments, vital signs and electrocardiograms (ECGs)</measure>
    <time_frame>Up to 180 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>IgA Nephropathy</condition>
  <arm_group>
    <arm_group_label>Part A: Atacicept 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Atacicept 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Atacicept 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Atacicept 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Atacicept 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atacicept 25 mg</intervention_name>
    <description>Subject will receive Atacicept 25 milligram (mg) once weekly as a subcutaneous (SC) injection for 72 weeks.</description>
    <arm_group_label>Part A: Atacicept 25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atacicept 75 mg</intervention_name>
    <description>Subject will receive Atacicept 75 mg once weekly as an SC injection for 72 weeks.</description>
    <arm_group_label>Part A: Atacicept 75 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subject will receive matching Placebo to atacicept once weekly as an SC injection for 72 weeks.</description>
    <arm_group_label>Part A: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atacicept 25 mg</intervention_name>
    <description>Subject will receive Atacicept 25 mg once weekly as an SC injection for 156 weeks.</description>
    <arm_group_label>Part B: Atacicept 25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atacicept 75 mg</intervention_name>
    <description>Subject will receive Atacicept 75 mg once weekly as an SC injection for 156 weeks</description>
    <arm_group_label>Part B: Atacicept 75 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atacicept 150 mg</intervention_name>
    <description>Subject will receive Atacicept 150 mg once weekly as an SC injection for 156 weeks.</description>
    <arm_group_label>Part B: Atacicept 150 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subject will receive matching Placebo to atacicept once weekly as an SC injection for 156 weeks.</description>
    <arm_group_label>Part B: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Greater than or equal to (&gt;=)18 years of age

          -  Biopsy-proven Immunoglobulin (IgA) nephropathy

          -  Urine Protein to Creatinine Ratio (UPCR) &gt;= 0.75 and &lt;= 6 milligram per milligram
             (mg/mg) during screening

          -  Stable and optimal dose of Angiotensin converting enzyme (ACE) inhibitor and/or
             angiotensin II receptor blockers (ARB) at least 8 weeks prior to screening

        Exclusion Criteria:

          -  Concomitant significant renal disease other than IgA nephropathy

          -  IgA nephropathy with significant glomerulosclerosis or cortical scarring

          -  Diagnosis of Henoch-Schonlein purpura

          -  Failure to meet estimated glomerular filtration rate (eGFR) and biopsy requirement
             criteria

          -  Serum IgG below 6 grams per liter (g/L)

          -  Use of cyclophosphamide ever or use of other immunosuppressants or systemic
             corticosteroids within 4 months

          -  Active infection requiring hospitalization or treatment with parenteral
             anti-infectives within 4 weeks

          -  History, or current diagnosis, of active tuberculosis (TB), or untreated latent TB
             infection

          -  History of or positive HIV and/or positive for hepatitis B or Hepatitis C at screening

          -  History of malignancy

          -  Nursing or pregnancy

          -  Any condition, including any uncontrolled disease state other than IgA nephropathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>EMD Serono Research &amp; Development Institute, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Medical Information</last_name>
    <phone>888-275-7376</phone>
    <email>service@emdgroup.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Merck KGaA Communication Center</last_name>
    <phone>49 6151 72 5200</phone>
    <email>service@merckgroup.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>California City</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo-To</state>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Leicester</city>
        <state>Leicestershire</state>
        <zip>LE5 4PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2016</study_first_submitted>
  <study_first_submitted_qc>June 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2016</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atacicept</keyword>
  <keyword>IgA Nephropathy</keyword>
  <keyword>BergerÂ´s disease</keyword>
  <keyword>Glomerulonephritis</keyword>
  <keyword>Proteinuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

